All Updates

All Updates

icon
Filter
Earnings/results
PureCycle earnings report forecasts revenue by Q4 2022
Bio-based Materials
Aug 12, 2021
This week:
Funding
EKORE raises EUR 1.3 million (~ USD 1 million) in seed funding to strengthen platform
Digital Twin
Dec 20, 2024
Funding
Culina Health raises USD 7.9 million in Series A funding to expand offerings and expand team
Functional Nutrition
Dec 19, 2024
FDA approval
ViGeneron receives IND clearance for VG801 gene therapy
Cell & Gene Therapy
Dec 19, 2024
Product updates
Reflex Aerospace ships first commercial satellite SIGI
Next-gen Satellites
Dec 19, 2024
Partnerships
Vast partners with SpaceX for two private astronaut missions to ISS
Space Travel and Exploration Tech
Dec 19, 2024
Management news
Carbios appoints Philippe Pouletty as interim CEO amid plant delay
Waste Recovery & Management Tech
Dec 19, 2024
Funding
BlueQubit raises USD 10 million in seed funding to develop quantum platform
Quantum Computing
Dec 19, 2024
FDA approval
Arbor Biotechnologies receives FDA clearance for ABO-101 IND application
Human Gene Editing
Dec 19, 2024
Funding
Partnerships
Personalis partners with Merck and Moderna for cancer therapy development and investment
Precision Medicine
Dec 19, 2024
Partnerships
COTA partners with Guardant Health to develop clinicogenomic data solutions for cancer research
Precision Medicine
Dec 19, 2024
Bio-based Materials

Bio-based Materials

Aug 12, 2021

PureCycle earnings report forecasts revenue by Q4 2022

Earnings/results

  • PureCycle Technologies, reported a net loss per share of USD 0.13 in Q2 2021,  surpassing analyst estimates of a loss of USD 0.16 per share, while also reporting a lower net loss per share compared to Q2 2020 (USD 0.19). However, operating losses for the quarter amounted to USD 9.9 million, up 247.2% year-over-year (YoY). This was due to increased R&D spend (nearly 25x the Q2 2020 R&D expense) and selling and administrative expenses (nearly 7x Q2 2020 expense). 

  • PureCycle did not provide any revenue or profit guidance for the next quarter nor for the full-year 2021. The company plans to complete its Plant 1 (also referred to as phase II facility) by the end of 2022, which is when it expects to generate revenue.

Key operational milestones as of H1 2021 include:

  • Plant 1 in Ironton, Ohio is on track and is being built within the budget. The module construction is expected to begin in Q3 2021 and go operational by 4Q 2022 with a total installed annual capacity of 107 million pounds.

  • Augusta, Georgia was decided as the location for Plant 2 and is expected to have five processing lines by Q4 2024 with a total annual capacity of 650 million pounds.

  • Plans to build  two more plants: one in Europe and another in an undecided location. The Europe plant is expected to go operational by Q2 2025 with one processing line and an annual capacity of 130 million pounds. The other plant will have three processing lines by Q4 2024 and an annual line capacity of 390 million pounds.

  • 40% of Plant 2 production will satisfy existing customer demands, and the company is also looking to sign additional agreements over Q3 2021.

  • Active negotiations to receive 300 million pounds of feedstock necessary for smooth production are in place.

  • Along with earnings, the company also announced that it has partnered with SK Global Chemical (a South Korean chemical company) in order to build a recycling facility and supply its ultra-pure polypropylene resin (UPRP) to the South Korean market.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.